PF-Atlas › Clinical Trials › NCT-GB0139

Inhaled GB0139 Galectin-3 Inhibitor in IPF

GB0139 · Galectin-3 Inhibition · Phase 2

Registry ID
NCT-GB0139
Phase
Phase 2
Status
Active, not recruiting
Drug / intervention
GB0139
Mechanism
Galectin-3 Inhibition
Sponsor
Galecto
Start
2021-09

About this trial

GB0139 is evaluated in NCT-GB0139, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Galecto, targeting galectin-3 inhibition. Current status: Active, not recruiting.

View NCT-GB0139 on ClinicalTrials.gov →

Explore related

Galectin-3 Inhibition — Treatment profileAll GB0139 trialsGalectin-3 Inhibition mechanismAll IPF trials

Related trials

GB0139 — NCT03832946
Medical disclaimer. This page summarizes public trial data for NCT-GB0139 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.